IMMUNOQUEST THERAPEUTICS AS

Signals

1 flags

• ▼ Negativ egenkapital 2025 Bokført egenkapital er negativ (−1,3 mill kr).

IMMUNOQUEST THERAPEUTICS AS is registered as a limited company in Oslo, Oslo with organisation number 931892266. The business is classified under research and experimental development on natural sciences and engineering (NACE 72.100). The company was incorporated in 2023. Registered share capital is NOK 45,000, divided into 44713 shares. The company's stated purpose is: “Forskning og utvikling av kreftbehandling.”. The most recent filed accounts, for the 2025 financial year, show NOK 0 in revenue and NOK −2.3m in operating profit.

Key figures · 2025

Revenue

NOK 0

Operating profit

NOK −2.3m

▼ −222 %

Equity

NOK −1.3m

▼ −80 %

Financial health · 2025

Liquidity

2.77

Very good

Current assets ÷ current liabilities

Profitability

-347.4%

Not satisfactory

Return on total assets

Solidity

-145.1%

Weak

Equity as a share of total capital

Solidity capped at Weak because equity is below NOK 100,000.

Who owns IMMUNOQUEST THERAPEUTICS AS?

INVEN2 AS Org. no. 995495899

60.0%

Jon Amund Kyte Private shareholder

20.0%

THE N AS Org. no. 933815188

20.0%

IMMUNOQUEST THERAPEUTICS AS

NOK 0 rev. · NOK −2.3m profit

IMMUNOQUEST THERAPEUTICS AS has 3 registered shareholders:

• INVEN2 AS 60.0%
• Jon Amund Kyte 20.0%
• THE N AS 20.0%

All shareholders and roles →

Frequently asked questions about IMMUNOQUEST THERAPEUTICS AS

Who owns IMMUNOQUEST THERAPEUTICS AS?

INVEN2 AS is the largest registered owner, with 60.0%.

What is the revenue of IMMUNOQUEST THERAPEUTICS AS?

IMMUNOQUEST THERAPEUTICS AS had revenue of NOK 0 in 2025.

Where is IMMUNOQUEST THERAPEUTICS AS based?

IMMUNOQUEST THERAPEUTICS AS has its business address in Oslo.

Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 03.10.2026.